The oncologist · 2026
Zanidatamab vs trastuzumab with or without PD-1 blockade in HER2-positive metastatic gastric cancer: a reconstructed patient-level pooled analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nichetti Federico, Nappo Floriana, Bof Francesca, Bosa Martina, Mattiuzzo Elena, Maddalena Giulia, De Grandis Maria Caterina, Murgioni Sabina, Bergamo Francesca, Lonardi Sara
Аннотация
BACKGROUND: First-line treatment of HER2-positive advanced gastric/GEJ adenocarcinoma now includes pembrolizumab added to trastuzumab plus chemotherapy (KEYNOTE-811). Zanidatamab, a bispecific anti-HER2 antibody, improved outcomes in HERIZON-GEA-01 but has not been directly compared with this standard.
METHODS: We searched PubMed, Scopus, and the ASCO/ESMO libraries for phase II/III trials of previously untreated HER2-positive metastatic gastric/GEJ adenocarcinoma. Individual patient data were reconstructed from published Kaplan-Meier curves. Cox frailty models estimated hazard ratios using the pembrolizumab regimen as the reference. Restricted mean survival time analysis was performed at 12, 24, and 36 months.
RESULTS: Nine trials were included: trastuzumab + chemotherapy (n = 1466), pembrolizumab + trastuzumab + chemotherapy (n = 430), zanidatamab + chemotherapy (n = 350), and zanidatamab + tislelizumab + chemotherapy (n = 335). Median PFS was 12.5 months with both zanidatamab regimens vs 10.0 months with pembrolizumab. The zanidatamab-tislelizumab triplet significantly reduced progression hazard (HR, 0.78, 95% CI, 0.62-0.99; P = 0.042). Median OS was 27.0 and 25.3 months with zanidatamab arms vs 20.3 months with pembrolizumab. Both zanidatamab arms showed significantly longer OS at 36 months by RMST.
CONCLUSIONS: Zanidatamab-based regimens were associated with longer PFS and OS than the pembrolizumab standard, though direct randomized comparisons are needed.
METHODS: We searched PubMed, Scopus, and the ASCO/ESMO libraries for phase II/III trials of previously untreated HER2-positive metastatic gastric/GEJ adenocarcinoma. Individual patient data were reconstructed from published Kaplan-Meier curves. Cox frailty models estimated hazard ratios using the pembrolizumab regimen as the reference. Restricted mean survival time analysis was performed at 12, 24, and 36 months.
RESULTS: Nine trials were included: trastuzumab + chemotherapy (n = 1466), pembrolizumab + trastuzumab + chemotherapy (n = 430), zanidatamab + chemotherapy (n = 350), and zanidatamab + tislelizumab + chemotherapy (n = 335). Median PFS was 12.5 months with both zanidatamab regimens vs 10.0 months with pembrolizumab. The zanidatamab-tislelizumab triplet significantly reduced progression hazard (HR, 0.78, 95% CI, 0.62-0.99; P = 0.042). Median OS was 27.0 and 25.3 months with zanidatamab arms vs 20.3 months with pembrolizumab. Both zanidatamab arms showed significantly longer OS at 36 months by RMST.
CONCLUSIONS: Zanidatamab-based regimens were associated with longer PFS and OS than the pembrolizumab standard, though direct randomized comparisons are needed.